Clinical Research Directory
Browse clinical research sites, groups, and studies.
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Summary
The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)
Official title: Safety and Efficacy of Cyclophosphamide and Ruxolitinib for Graft-versus-host-disease Prophylaxis After Hematopoietic Stem Cell Transplantation With Thymoglobulin Serotherapy in Conditioning Regimen in Patients With Inborn Errors of Immunity
Key Details
Gender
All
Age Range
0 Months - 21 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-11-21
Completion Date
2027-12-31
Last Updated
2024-01-10
Healthy Volunteers
No
Conditions
Interventions
Cyclophosphamide
Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
Ruxolitinib
Ruxolitinib 7 mg/m2 from day +5 after HSCT
Locations (1)
HSCT department
Moscow, Russia